Liberel Mite (Desogestrel, Ethinylestradiol)

Liberel Mite, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.

• Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential.
• Management of menstrual disorders: helps regulate cycle length and reduce heavy bleeding.
• Treatment of moderate acne: reduces androgen‑driven skin lesions in eligible patients.

• Desogestrel/Ethinylestradiol exerts its contraceptive effect by suppressing the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby inhibiting ovulation. Ethinylestradiol stabilises the endometrial lining, while desogestrel alters cervical mucus, creating a hostile environment for sperm penetration and fertilisation.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Breast tenderness: discomfort or swelling of breast tissue.
• Headache: occasional throbbing or tension‑type pain.
• Spotting: irregular breakthrough bleeding, especially during the first cycles.
• Mood changes: mild irritability or emotional fluctuations.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Hypertension: significant increase in blood pressure.
• Liver disorders: benign hepatic adenoma or cholestatic jaundice.
• Gallbladder disease: formation of gallstones or cholecystitis.
• Severe allergic reaction: anaphylaxis, angioedema, or urticaria.

Before initiating therapy, clinicians should evaluate individual risk factors and counsel patients on safe use.

• Medical assessment: screen for history of thromboembolism, cardiovascular disease, or smoking.
• Age consideration: avoid use in women over 35 who smoke heavily.
• Liver function: monitor in patients with hepatic impairment.
• Migraine history: caution in those with migraine with aura.
• Concomitant medications: review for drugs that may affect hormonal efficacy.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Combined oral contraceptives can be affected by several drug classes.

Major Interactions (Avoid)

• Strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce contraceptive effectiveness.
• Antiretroviral protease inhibitors (e.g., ritonavir): can alter hormone levels.
• St. John's wort: potent CYP3A4 inducer that may compromise efficacy.

Moderate Interactions (Monitor Closely)

• Antifungals (e.g., ketoconazole, itraconazole): may increase hormone concentrations.
• Selective serotonin reuptake inhibitors (SSRIs): occasional alteration of bleeding patterns.
• Antihypertensives (e.g., ACE inhibitors): monitor blood pressure as hormonal changes can affect control.